SCHEMBL2735908

SCHEMBL2735908

Cc1ccc(F)c(CNC(=O)c2[nH]c3ccc(F)cc3c2-c2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 2/20 0.55
ALDH1A1 P00352 6/20 0.54
MEN1 O00255 6/20 0.54
KMT2A Q03164 6/20 0.54
KDM4E B2RXH2 3/20 0.54
HTT P42858 2/20 0.54
HPGD P15428 2/20 0.54
GFER P55789 1/20 0.54
HSD17B10 Q99714 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.52
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
MAPT P10636 3/20 0.49
GAA P10253 3/20 0.49
POLB P06746 2/20 0.47
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2735909 0.89 MAP2 (0.60) MAP2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL2735928 0.88 MAPT (0.60) MAP2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL2760045 0.86 MAP2 (0.53) MAP2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL13197343 0.85 MAP2 (0.56) MAP2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL2735919 0.83 MAP2 (0.56) MAP2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL2735905 0.82 MAP2 (0.58) MAP2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL2735912 0.82 MAP2 (0.58) MAP2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL2735907 0.82 MAP2 (0.58) MAP2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL2735904 0.82 ALDH1A1 (0.60) MAP2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL2735926 0.82 MAP2 (0.62) MAP2ALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088768-B2 Protein kinase and phosphatase inhibitors THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) 2012-01-03 US disclosed
US-20110136807-A1 Bicyclic compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2011-06-09 US disclosed
US-20110028474-A1 PROTEIN KINASE AND PHOSPHATASE INHIBITORS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2011-02-03 US disclosed
US-7427608-B2 Protection against and treatment of hearing loss THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2008-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028474-A1 PROTEIN KINASE AND PHOSPHATASE INHIBITORS PTPN5, PTPN2, PTPN4 MAP2 672/4885ALDH1A1 4474/4885MEN1 3808/4885
US-20110136807-A1 Bicyclic compositions and methods for modulating a kinase cascade MAP3K20, MAP3K6, MAP3K2 MAP2 806/4885ALDH1A1 4720/4885MEN1 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.